Executive search firm Toft Group has placed Dr. Matthew Vincent as Vice President Business Development focused on the North American market. Dr. Vincent is a senior executive with over 25 years’ experience in multiple areas of biotechnology and life science. He joins Avacta from Arisaph Pharmaceuticals where he led corporate development and therapeutic innovation strategy delivering around $100m in license revenues in the past three years. Prior to Arisaph, Matthew was Director of Business Development at Ocata Therapeutics where he had responsibility for all commercial affairs including product licensing and divestment, asset acquisition and complex commercial negotiations as well as the eventual acquisition of Ocata by Astellas Pharmaceuticals. Matthew’s experience also includes developing therapeutic product profiles for regenerative medicine and immuno-oncology, pricing/reimbursement and regulatory strategy. From his previous work as a lawyer and patent attorney, he has experience in worldwide patent portfolio strategy and IP diligence, regulatory affairs strategy, private and public financing and patent litigation.
About Avacta Life Sciences
Avacta Group plc is dedicated to providing life scientists with high quality, powerful tools to enable them to work faster and smarter in accelerating our understanding of biology and disease, and to help them apply these advances to diagnosis and treatment.
Avacta came to the AIM market in 2006 to provide instrumentation, consumables and reagents for life science researchers. The Group’s activities are now focused on Affimer® technology, an engineered alternative to antibodies, which it is commercializing through Avacta Life Sciences.